$284.27▴ 0.06%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 59% above our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Ligand Pharmaceuticals Incorporated's earnings-quality signal is not available yet.
Key numbers
Recent news
Ligand to Participate in September Investor Conferences
3 Overlooked Stocks Positioned for the Next Market Rotation
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date